


## PHARMACEUTICAL 2020

## Flexion Therapeutics Inc Rank 238 of 362





## PHARMACEUTICAL 2020

## Flexion Therapeutics Inc Rank 238 of 362

The relative strengths and weaknesses of Flexion Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Flexion Therapeutics Inc compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 56% points. The greatest weakness of Flexion Therapeutics Inc is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 95% points.

The company's Economic Capital Ratio, given in the ranking table, is -277%, being 26% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	195,675
Cost of Goods Sold	9,960
Intangible Assets	0
Liabilities, Current	36,219
Liabilities, Non-Current	48,036
Other Assets	8,223
Other Compr. Net Income	139
Other Expenses	0
Other Liabilities	153,413
Other Net Income	-13,502
Property and Equipment	13,662
Research and Development	69,559
Revenues	72,957
Selling, General and Administrative Expense	129,709

Output Variable	Value in 1000 USD
Assets	217,560
Liabilities	237,668
Expenses	209,228
Stockholders Equity	-20,108
Net Income	-149,773
Comprehensive Net Income	-149,704
Economic Capital Ratio	-277%